Vancomycin + piperacillin / tazobactam ups kidney risk

Vancomycin + piperacillin/ tazobactam ups kidney risk

(HealthDay)—For hospitalized children, coadministration of intravenous (IV) vancomycin and piperacillin/tazobactam is associated with increased risk of acute kidney injury (AKI), according to a study published online Oct. 2 in JAMA Pediatrics.

Kevin J. Downes, M.D., from The Children's Hospital of Philadelphia, and colleagues conducted a involving children hospitalized for three or more days who received IV vancomycin plus one other antipseudomonal β-lactam combination therapy. Data were included for 1,915 hospitalized children who received combination therapy.

The researchers found that 8.2 percent of patients had antibiotic-associated AKI, including 11.7 percent of the 1,009 patients who received IV vancomycin plus piperacillin/tazobactam combination therapy. IV vancomycin plus piperacillin/tazobactam combination therapy correlated with elevated odds of AKI each hospital day compared with therapy plus one other antipseudomonal β-lactam antibiotic combination after adjustment for age, intensive care unit level of care, receipt of nephrotoxins, and hospital (adjusted odds ratio, 3.4).

"Pediatricians must be cognizant of the potential added risk of this when making empirical antibiotic choices," the authors write.

Several authors disclosed financial ties to the biopharmaceutical industry.


Explore further

Pharmacists' study helps prevent antibiotic-induced kidney failure

More information: Abstract/Full Text
Journal information: JAMA Pediatrics

Copyright © 2017 HealthDay. All rights reserved.

Citation: Vancomycin + piperacillin / tazobactam ups kidney risk (2017, October 3) retrieved 18 November 2019 from https://medicalxpress.com/news/2017-10-vancomycin-piperacillin-tazobactam-ups-kidney.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
0 shares

Feedback to editors

User comments